We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Increased Bleb Formation Characterizes Metastatic Cancer Cells

By LabMedica International staff writers
Posted on 04 Jun 2019
A recent paper described an inexpensive fluid biopsy device that is able to distinguish highly metastatic prostate cancer cells from moderately metastatic prostate cancer cells and normal cells.

Since most prostate tumor cells that survive current treatment regimens become metastatic, there is an urgent need for new tools to detect metastatic prostate cancer that do not rely on prostate specific antigen (PSA) measurements, which cannot accurately identify cells with metastatic potential.

Plasma membrane blebbing (in which portions of the cell’s outer layer bulges outward from the more rigid inner layer) is known to provide important metastatic capabilities to cancer cells by aiding cell detachment from the primary tumor site and increasing cell deformability to promote cell migration through the extracellular matrix. More...
In fact, highly metastatic prostate cancer cells flowing through a microfluidic channel form 27% more plasma membrane blebs than normal cells and have a lower stiffness (about 50%).

Taking advantage of this property, investigators at Texas Tech University (Lubbock, USA) developed an instrument that measured bleb formation as the device forced cell samples through minute channels less than 10 microns wide. Results obtained by this method revealed that highly metastatic prostate cancer cells exhibited more blebbing than did moderately metastatic or normal cells. Of the highly metastatic cells 56% produced blebs, whereas only 29% of normal cells and 38% of moderately metastatic cells did.

Mechanistically, increased blebbing by highly metastatic cells was attributed to low levels of the protein F-actin, which resulted in a reduced number of binding sites for proteins that normally anchor the cell’s plasma membrane to the inner cortex.

“This is a potentially significant finding which may provide simple and inexpensive diagnostic methods for detecting early and advanced cancer, particularly metastatic cancer,” said senior author Dr. Fazle Hussain, professor of mechanical engineering at Texas Tech University.

The fluid biopsy device for detection of highly metastatic prostate cancer cells was described in the May 21, 2019, online edition of the journal Biomicrofluidics.

Related Links:
Texas Tech University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.